Rewind Therapeutics extends Series A financing
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Henkel buys FDCA from Avantium NV
/in News/by Thomas GabrielczykBioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.
Vésale Bioscience wins R&D grant
/in News/by Thomas GabrielczykPhage therapy specialist Vésale Bioscience gas bageds 1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
Abionyx Pharma announces success in fighting sepsis-triggered AKI
/in News/by Thomas GabrielczykAbionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury […]
BioNTech bags Instadeep for £562m
/in News/by Thomas GabrielczykBioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Roche withdraws checkpoint blocker from the market
/in News/by Thomas GabrielczykRoche AGs US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
/in News/by Thomas GabrielczykWith the help of a 25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Hummingbird and Synaffix in $150m ADC deal
/in News/by Thomas GabrielczykRational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Ethris inks 15m deal with Indian Ciplas
/in News/by Thomas GabrielczykCipla EU Ltd is going to make an equity investment of 15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
First hints for leukopenia diagnostic in MS
/in News/by Thomas GabrielczykScientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.